RELMADA THERAPEUTICS, INC.
Income Statement
| Line Item | Mar 2020 | Mar 2019 | Feb 2014 | Nov 2013 | Aug 2013 | May 2013 | Feb 2013 | Nov 2012 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.9K | $6.3K | $682 | $1.9K | $0 | $634 | $2.3K | $2.1K |
| Cost of Revenue | — | — | $685 | $1.7K | $0 | $322 | $1.9K | $1.9K |
| Gross Profit | — | — | $-3 | $164 | $0 | $312 | $482 | $299 |
| Gross Margin | — | — | -0.4% | 8.9% | — | 49.2% | 20.5% | 13.9% |
| Operating Expenses | ||||||||
| Research & Development | $4.5M | $1.3M | — | — | — | — | — | — |
| SG&A Expense | $5.5M | $1.4M | $3.1K | $14.5K | — | $19.8K | $3.9K | $9.0K |
| Operating Income | $-10.0M | $-2.7M | $-3.1K | $-14.4K | — | $-19.5K | $-4.1K | $-9.0K |
| Operating Margin | -203,560.0% | -42,889.0% | -458.1% | -777.0% | — | -3,073.3% | -176.7% | -419.7% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $-10.7M | $-2.7M | — | $-14.4K | $-12.4K | $-19.5K | $-4.1K | $-9.0K |
| Net Margin | -217,822.8% | -42,636.0% | — | -777.0% | — | -3,073.3% | -176.7% | -419.7% |
| EPS (Basic) | $-0.72 | $-0.36 | $0.00 | $0.00 | — | $0.00 | $0.00 | $0.00 |
| EPS (Diluted) | $-0.72 | $-0.36 | $0.00 | $0.00 | — | $0.00 | $0.00 | $0.00 |
| Shares Outstanding (Basic) | 14.9M | 31.0M | — | — | — | — | — | — |
| Shares Outstanding (Diluted) | 14.9M | 31.0M | — | — | — | — | — | — |
| Dividends Per Share | — | — | — | — | — | — | — | — |